FDA's NDA And BLA Approvals: Xhance, Trelegy Ellipta, Clorotekal, Verzenio
Executive Summary
Original new drugs and biologics approved by US FDA.
You may also be interested in...
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
GlaxoSmithKline is poised for a challenging 2018, with an interchangeable Advair generic expected to launch, but GSK believes growth from new products will make up some of the loss. US Advair sales could be slashed to £750m from £1.6bn in 2017.